3-溴-6-氯咪唑并[1,2-a]吡啶 | 886371-28-4

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 3-溴-6-氯咪唑并[1,2-a]吡啶
• 中文别名: 3-溴-6-氯咪唑并[1,2-A]吡啶；3-溴-6-氯咪唑并[1,2-α]吡啶；3-溴-6-氯-咪唑并[1,2-a]吡啶
• 英文名称: 3-bromo-6-chloroimidazo[1,2-a]pyridine
• CAS: 886371-28-4
• 化学式: C₇H₄BrClN₂
• mdl: MFCD08667858
• 分子量: 231.479
• InChiKey: LIBKDAUSMLPFBF-UHFFFAOYSA-N

物化性质

• 熔点：
  105-107℃
• 密度：
  1.84

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P280
• 危险性描述：
  H302,H317

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3-Bromo-6-chloroimidazo[1,2-a]pyridine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
3-Bromo-6-chloroimidazo[1,2-a]pyridine
Ingredient name:
CAS number: 886371-28-4

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H4BrClN2
Molecular weight: 231.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-溴-6-氯咪唑并[1,2-a]吡啶 、 4-甲苯硼酸 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 5.0h， 以98%的产率得到6-chloro-3-(p-tolyl)imidazo[1,2-a]pyridine
  参考文献：
  名称：

  Cyrene 作为 Suzuki-Miyaura 交叉偶联的生物基溶剂

  摘要：

  Suzuki-Miyaura (SM) 交叉偶联是化学工业中使用最广泛的 Pd 催化的 C-C 键形成反应。大部分 SM 偶联剂使用偶极非质子溶剂；然而，当前的可持续性举措和日益严格的法规提倡使用具有更理想特性的替代品。在这里，我们描述了生物衍生溶剂 Cyrene™ 在 SM 交叉偶联中的范围和效用，并评估其作为反应介质的适用性，以实现从发现到克级规模的这一基准转化。

  DOI：

  10.1055/s-0036-1589143
• 作为产物：
  描述：

  6-氯咪唑并[1,2-a]吡啶 在 溴 作用下， 以 溶剂黄146 为溶剂， 反应 1.0h， 生成 3-溴-6-氯咪唑并[1,2-a]吡啶
  参考文献：
  名称：

  [EN] IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS
  [FR] COMPOSÉS ORGANIQUES

  摘要：

  公开号：

  WO2009050183A3

文献信息

• Dimethylisosorbide (DMI) as a Bio-Derived Solvent for Pd-Catalyzed Cross-Coupling Reactions
  作者：Allan Watson、Kirsty Wilson、Jane Murray、Helen Sneddon、Craig Jamieson

  DOI：10.1055/s-0037-1611054

  日期：2018.10

  Palladium-catalyzed bond-forming reactions, such as the ­Suzuki–Miyaura and Mizoroki–Heck reactions, are some of the most broadly utilized reactions within the chemical industry. These reactions frequently employ hazardous solvents; however, to adhere to increasing sustainability pressures and restrictions regarding the use of such solvents, alternatives are highly sought after. Here we demonstrate the utility of dimethyl isosorbide (DMI) as a bio-derived solvent in several benchmark Pd-catalyzed reactions: Suzuki–Miyaura (13 examples, 62–100% yield), Mizoroki–Heck (13 examples, 47–91% yield), and Sonogashira (12 examples, 65–98% yield).

  钯催化的键合反应，如Suzuki–Miyaura和Mizoroki–Heck反应，在化工行业中被广泛使用。这些反应通常使用危险溶剂；然而，为了遵守日益增加的可持续性压力和有关使用此类溶剂的限制，人们迫切寻求替代方案。在这里，我们展示了二甲基异山梨醇醚（DMI）作为生物衍生溶剂在几种基准Pd催化反应中的实用性：Suzuki–Miyaura（13个示例，收率62–100%），Mizoroki–Heck（13个示例，收率47–91%）和Sonogashira（12个示例，收率65–98%）。
• Organic Compounds
  申请人：Shaw Duncan

  公开号：US20100210641A1

  公开（公告）日：2010-08-19

  Compounds of formula I: in free or salt or solvate form, where R 1 , R 2 , R 3 and R 20 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis.

  式I的化合物：以自由或盐或溶剂形式存在，其中R1，R2，R3和R20具有规范中指定的含义，可用于治疗由ALK-5和/或ALK-4受体介导的疾病。还描述了含有这些化合物的制药组合物和制备这些化合物的方法。这些化合物对于治疗炎症或阻塞性呼吸道疾病，如肺动脉高压，肺纤维化，肝纤维化，癌症，肌肉疾病，如肌肉萎缩和肌肉营养不良，以及全身性骨骼疾病，如骨质疏松症非常有用。
• Organic compounds
  申请人：Shaw Duncan

  公开号：US08367662B2

  公开（公告）日：2013-02-05

  Compounds of formula I: in free or salt or solvate form, where R1, R2, R3 and R20 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis.

  公式I的化合物：以自由形式、盐形式或溶剂合形式存在，其中R1、R2、R3和R20的含义如规范所示，可用于治疗由ALK-5和/或ALK-4受体介导的疾病。还描述了包含这些化合物的药物组合物和制备这些化合物的过程。这些化合物可用于治疗炎性或阻塞性呼吸道疾病，如肺动脉高压、肺纤维化、肝纤维化、癌症、肌肉疾病，如肌肉萎缩和肌肉萎缩症，以及全身骨骼疾病，如骨质疏松症。
• IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS
  申请人：Novartis AG

  公开号：EP2212323B1

  公开（公告）日：2012-08-15
• US8367662B2
  申请人：——

  公开号：US8367662B2

  公开（公告）日：2013-02-05